434 related items for PubMed ID: 17698695
1. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H.
Arch Neurol; 2007 Oct; 64(10):1407-15. PubMed ID: 17698695
[Abstract] [Full Text] [Related]
2. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.
Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L, BHT-3009 Study Group.
Ann Neurol; 2008 May; 63(5):611-20. PubMed ID: 18481290
[Abstract] [Full Text] [Related]
3. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT.
Neurology; 2008 Oct 28; 71(18):1390-5. PubMed ID: 18525027
[Abstract] [Full Text] [Related]
4. DNA-based vaccines: the future of multiple sclerosis therapy?
Stüve O, Cravens PD, Eagar TN.
Expert Rev Neurother; 2008 Mar 28; 8(3):351-60. PubMed ID: 18345967
[Abstract] [Full Text] [Related]
5. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V.
Mult Scler; 2010 Apr 28; 16(4):450-4. PubMed ID: 20150398
[Abstract] [Full Text] [Related]
6. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ.
Clin Ther; 2006 Apr 28; 28(4):461-74. PubMed ID: 16750460
[Abstract] [Full Text] [Related]
7. BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis.
Correale J, Fiol M.
Curr Opin Mol Ther; 2009 Aug 28; 11(4):463-70. PubMed ID: 19649992
[Abstract] [Full Text] [Related]
8. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
Clin Ther; 2008 Jun 28; 30(6):1102-12. PubMed ID: 18640466
[Abstract] [Full Text] [Related]
9. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
[Abstract] [Full Text] [Related]
10. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
Arch Neurol; 2008 Feb 04; 65(2):199-204. PubMed ID: 18071030
[Abstract] [Full Text] [Related]
11. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G, Filippi M, Wolinsky JS.
Ann Neurol; 2001 Mar 04; 49(3):290-7. PubMed ID: 11261502
[Abstract] [Full Text] [Related]
12. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T, Laquinimod in Relapsing MS Study Group.
Neurology; 2005 Mar 22; 64(6):987-91. PubMed ID: 15781813
[Abstract] [Full Text] [Related]
13. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
[Abstract] [Full Text] [Related]
14. Defining interferon beta response status in multiple sclerosis patients.
Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E.
Ann Neurol; 2004 Oct 26; 56(4):548-55. PubMed ID: 15389896
[Abstract] [Full Text] [Related]
15. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K, PRIVIG Study Group, UBC MS/MRI Research Group.
Neurology; 2008 Jul 22; 71(4):265-71. PubMed ID: 18645164
[Abstract] [Full Text] [Related]
16. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC.
Neurology; 2009 Feb 24; 72(8):705-11. PubMed ID: 19073945
[Abstract] [Full Text] [Related]
17. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R, Teriflunomide Multiple Sclerosis Trial Group, University of British Columbia MS/MRI Research Group.
Neurology; 2006 Mar 28; 66(6):894-900. PubMed ID: 16567708
[Abstract] [Full Text] [Related]
18. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW, GA/minocycline study investigators.
Mult Scler; 2009 Oct 28; 15(10):1183-94. PubMed ID: 19776092
[Abstract] [Full Text] [Related]
19. Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis.
Broadley SA, Vanags D, Williams B, Johnson B, Feeney D, Griffiths L, Shakib S, Brown G, Coulthard A, Mullins P, Kneebone C.
Mult Scler; 2009 Mar 28; 15(3):329-36. PubMed ID: 19039022
[Abstract] [Full Text] [Related]
20. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR, Panitch HS.
Clin Ther; 2007 Sep 28; 29(9):2031-48. PubMed ID: 18035202
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
